Frank Behrens, MD

Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Germany
Frankfurt am Main, Germany

Rheumatologist

Disclosure information not submitted.

Presentation(s):

• 0199: Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes - 16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis

  Saturday, November 12, 2022
  1:45 PM – 1:50 PM Eastern Time

• 1597: Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits in Patients with Active Psoriatic Arthritis: Results from a 16-Week Randomized, Placebo-Controlled Phase 2 Clinical Trial

  Sunday, November 13, 2022
  3:00 PM – 3:10 PM Eastern Time